MEN 2 (Multiple endocrine neoplasia Typ 2)

MEN 2 (Multiple endocrine neoplasia Typ 2)

Multiple Endocrine Neoplasias (MEN) and Polyglandular Autoimmune Endocrinopathies

MEN 2 (Multiple Endocrine Neoplasia Type 2)
MEN 2 is a rare, genetically determined syndrome caused by mutations in the RET proto-oncogene. It leads to the development of tumors in various hormone-producing glands.

Subtypes of MEN 2

  1. MEN 2A:

  • Frequency: More common than MEN 2B.

  • Characteristics:

    • Medullary thyroid carcinoma (MTC):

      • Almost always present, arising from the C cells of the thyroid.

    • Pheochromocytoma:

      • Tumor of the adrenal medulla → leads to excess adrenaline and noradrenaline production, causing hypertension.

    • Primary hyperparathyroidism:

      • Overactivity of the parathyroid glands → leads to elevated calcium levels in the blood.

  1. MEN 2B:

  • Frequency: Rarer but more aggressive.

  • Characteristics:

    • Medullary thyroid carcinoma (as in MEN 2A, but earlier onset and more aggressive).

    • Pheochromocytoma.

    • Additional features:

      • Marfanoid habitus (tall, slender, long limbs).

      • Ganglioneuromas (benign tumors of the gastrointestinal tract and mucous membranes).

      • Early-onset neurological and gastrointestinal symptoms.

Genetic Cause

  • RET gene mutation:

    • Location: Chromosome 10.

    • Effect: Activating mutation → uncontrolled cell growth and tumor formation.

    • Inheritance: Autosomal dominant; 50% chance of transmission.

  1.  

Diagnosis

  • Genetic testing: Detection of RET mutation.

  • Calcitonin measurement: Early marker for medullary thyroid carcinoma.

  • Calcitonin stimulation test:

    • Pentagastrin test (no longer available) or calcium stimulation test.

    • Pathological values: Calcitonin >200 pg/ml → suspicion of MTC.

  • Imaging:

    • MRI/CT for detection of pheochromocytomas.

  • Family history: Important for identifying genetic predisposition.

Therapy

  1. Medullary thyroid carcinoma (MTC):

    • Prophylactic thyroidectomy: Early surgical removal of the thyroid in RET mutation carriers.

      • In MEN 2B, recommended already in childhood.

      • In MEN 2A, depending on the risk category.

  2. Pheochromocytoma:

    • Surgical removal of the adrenal gland.

    • Preoperative stabilization with alpha- and beta-blockers.

  3. Primary hyperparathyroidism:

    • Surgical removal of the parathyroid glands.

Early Detection and Surveillance

  • Regular calcitonin measurements for early detection of MTC.

  • Imaging studies (e.g., MRI, CT) for tumor monitoring.

  • Genetic screening of first-degree relatives for early intervention.

Summary
MEN 2 is a genetic syndrome that should be detected and treated at an early stage. RET mutation testing enables preventive therapy, which significantly improves prognosis. Close monitoring and interdisciplinary management are essential to ensure quality of life for affected individuals.

Polyglandular Autoimmune Endocrinopathies (PGA / APS)

Polyglandular autoimmune endocrinopathies (also called Autoimmune Polyglandular Syndromes, APS) are rare disorders in which the immune system attacks multiple hormone-producing glands, leading to their dysfunction. They are classified into different types:

APS Type 1 (Juvenile Type):

  • Onset: Usually in childhood.

  • Cause: Mutations in the AIRE gene (Autoimmune Regulator) on chromosome 21.

  • Main features (classic triad):

    • Chronic mucocutaneous candidiasis.

    • Hypoparathyroidism.

    • Primary adrenal insufficiency (Addison’s disease).

  • Other possible manifestations: Alopecia, vitiligo, type 1 diabetes, pernicious anemia, hypogonadism.

APS Type 2 (Schmidt’s Syndrome):

  • Onset: Usually in adulthood.

  • Inheritance: Polygenic, associated with HLA-DR3 and HLA-DR4.

  • Main features:

    • Addison’s disease (mandatory).

    • Autoimmune thyroid disease (e.g., Hashimoto’s thyroiditis, Graves’ disease).

    • Type 1 diabetes mellitus.

  • Other possible autoimmune conditions: Celiac disease, pernicious anemia, vitiligo, primary ovarian insufficiency.

APS Type 3:

  • Definition: Combination of autoimmune thyroid disease with other autoimmune disorders, but without Addison’s disease.

  • Typical associations:

    • Type 1 diabetes.

    • Pernicious anemia.

    • Vitiligo.

    • Celiac disease.

APS Type 4:

  • Definition: Other rare combinations of autoimmune endocrinopathies that do not fit into types 1–3.

Diagnosis

  • Clinical suspicion based on the involvement of multiple endocrine organs.

  • Hormonal testing depending on the suspected glandular insufficiency.

  • Autoantibody screening (e.g., anti-21-hydroxylase, anti-TPO, anti-GAD).

  • Genetic testing (AIRE mutation in APS-1).

Therapy

  • Lifelong hormone replacement depending on the affected glands:

    • Hydrocortisone/fludrocortisone for Addison’s disease.

    • Levothyroxine for hypothyroidism.

    • Insulin for type 1 diabetes.

    • Calcium/vitamin D for hypoparathyroidism.

  • Antifungal treatment for chronic candidiasis (in APS-1).

  • Regular monitoring for the development of new autoimmune conditions.

Summary
Polyglandular autoimmune endocrinopathies are complex syndromes characterized by the autoimmune destruction of multiple hormone-producing organs. Early diagnosis, lifelong hormone replacement, and careful surveillance are essential to improve prognosis and quality of life.